Business · 03/08/2006Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for EMEND Patent Extension
Summary
The Food and Drug Administration (FDA) has officially announced the regulatory review period for the patent extension of EMEND, a human drug product, following a submission to the Director of Patents and Trademarks at the Department of Commerce.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →